HIV serostatus, inflammatory biomarkers and the frailty phenotype among older people in rural KwaZulu-Natal, South Africa. by Edwards, Anita et al.
HIV serostatus, inflammatory biomarkers and the frailty phenotype among 
older people in rural KwaZulu-Natal, South Africa 
 
Anita Edwards1, Mark J Siedner1,4, Stephen Nash2 , Melissa Neuman2, 
Sivapragashini Danaviah1, Theresa Smit1, Dickman Gareta1; Paul Kowal3; Janet 
Seeley1,2; 
1. Africa Health Research Institute, KwaZulu-Natal, South Africa 
2. London School of Hygiene and Tropical Medicine 
3. World Health Organization, Division of Data, Analytics and Delivery for Impact 
4. Harvard Medical School 
 
Anita Edwards PhD 
Mark J Siedner MD MPH 
Stephen Nash MSc 
Melissa Neuman ScD MSc 
Sivapragashini Danaviah PhD 
Theresa Smit PhD 
Dickman Gareta MSc 
Paul Kowal PharmD 
Janet Seeley PhD 
Corresponding author anita.edwards@ahri.org +27(0)832307704 
 
Funding 
This study was funded by the US National Institutes of Health AG (WHO 
2016/583903-0) through WHO. 
Stephen Nash and Melissa Neuman are supported by an award jointly funded by the 
UK Medical Research Council (MRC) and the UK Department for International 
Development (DFID) under the MRC/DFID Concordat agreement, which is also part 




We are grateful to all the participants for giving us their time and sharing their 
information for this study.  We thank the wider community in uMkhanyakude for their 
support of our research.  We are grateful to Sithembile Msane and Ntombi Mkwanazi 
for data collection and for their enthusiasm for the study and the support of research 
with older people. We thank Dr Somnath Chatterji and Nirmala Naidoo who lead the 
study at WHO and Dr Ties Boerma former lead for the study, for their help and 
support.  We also thank Kathy Baisley, LSHTM for help with the sampling.  Lastly, we 
are grateful to the AHRI Diagnostic Laboratory staff for assistance with kit 




We compared the prevalence of frailty by HIV serostatus and related biomarkers to 
the modified frailty phenotype among older individuals in a rural population in South 
Africa.  
Methods  
Questionnaire data were from a cohort of people living with HIV (PWH) on 
antiretroviral therapy (ART) and HIV-uninfected people aged 50 years and older 
sampled from the Africa Health Research Institute Demographic Health and 
Surveillance area in northern KwaZulu-Natal.  The prevalence of frailty was 
compared using five categories: 1) physical activity; 2) mobility; 3) fatigue; 4) gait 
speed; 5) grip strength and assessed for demographic, clinical, and inflammatory 
correlates of frailty.  
Results 
Among 614 individuals in the study, 384(62.5%) were women. The median age at 
study enrolment was 64 years [Interquartile range (IQR) (58.6-72.0)]. 292 (47.6%) 
were PWH.499 (81%) were classified as either pre-frail or frail. 43 (7%) were frail and 
HIV positive,185 (30%) were pre-frail and HIV positive, 57 were frail and HIV 
negative and 214 (35%) were pre-frail and HIV negative. Frailty was similar for HIV 
negative and PWH (17.7% vs 14.7%, P-value 0.72). Women were more likely to be 
frail (18.3% vs. 13.04%, P-value 0.16). The prevalence of frailty increased with age 
for both HIV groups. In the multivariable analysis, the odds of being frail were higher 
in those aged 70 years and above than those aged between 50 and 59 years 
(P<0.001). Females were less likely to be pre-frail than males (P<0.001). There was 
no association between any of the inflammatory biomarkers and frailty and pre-frailty. 
Conclusion 
In this population the prevalence of frailty is similar for PWH and people without HIV, 
but higher for women than men. These data suggest that the odds of developing 
frailty is similar for PWH over the age of 50 years, who survive into older age, as for 
people without HIV.  
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Introduction  
Frailty is characterised by a decline in functioning across multiple organ systems and 
is associated with a greater risk of adverse outcomes (Hoogendijk et al., 2019). 
Frailty prevalence increases with age, but it occurs independently from chronological 
age (Dent, Kowal, & Hoogendijk, 2016). With current available therapies, people 
living with HIV (PWH) are living longer, but are at higher risk of age-related health 
concerns, including frailty. HIV infection can induce biologically similar mechanisms 
as aging (Brothers & Rockwood, 2014; Gross et al., 2016), and, historically, the 
clinical trajectory of HIV disease has been shown to mimic the frailty phenotype in 
the United States, particularly at advanced stages of HIV infection (Desquilbet et al., 
2007). Indeed, data from high-income countries suggests that as PWH age, they 
experience increased vulnerability to multimorbidity, and appear to be at risk for an 
earlier onset of the phenotype of frailty  (Bloch, 2018; Desquilbet et al., 2007; Fried et 
al., 2001; Levett, Cresswell, Malik, Fisher, & Wright, 2016; Önen et al., 2009; Thurn 
& Gustafson, 2017). 
 
Although the exact mechanisms of this increased risk of frailty are not clear, chronic 
immune activation and cellular senescence related to HIV infection have been 
indicated (Desai & Landay, 2010; Piggott, Erlandson, & Yarasheski, 2016). Similar 
causal pathways may be contributing to both frailty and the course of HIV infections - 
increased levels of circulating cytokines (C-reactive protein [CRP], tumour necrosis 
factor alpha [TNF-α] and interleukin-6 [IL-6]) are amongst the immunological features 
related to ageing and frailty previously described (Althoff et al., 2013; Hubbard, 
O’Mahony, Calver, & Woodhouse, 2008; Li, Manwani, & Leng, 2011). Consequently 
treated HIV has been classified as a disease associated with both accelerated and 
accentuated ageing, with effects seen both on cellular ageing and ageing 
phenotypes (Pathai, Bajillan, Landay, & High, 2014). 
 
Although the majority of work in this area has come from cohort studies in the United 
States, there has been increasing attention to risks of frailty and disability among the 
large, and aging population of PWH in sub-Saharan Africa (Mugisha et al., 2016; 
Nyirenda et al., 2013; Pathai, Gilbert, et al., 2013).  Importantly, the clinical spectrum 
of HIV infection in sub-Saharan Africa has changed greatly in the last decade, with 
the widespread distribution of antiretroviral therapy (ART). This has resulted in a 
decrease in AIDS-related morbidity and mortality, and an increase in the number of 
people living into old age with HIV infection (Negin, Mills, & Bärnighausen, 2012; 
Vollmer et al., 2017).  
 
Preliminary data from South Africa in the early ART era, showed greater numbers of 
people with HIV than uninfected comparators, meeting frailty criteria (Pathai, Gilbert, 
et al., 2013; Pathai, Lawn, et al., 2013). Moreover, chronic immune activation despite 
treatment-mediated virologic suppression has been demonstrated in the region 
(Siedner et al., 2018). However, there is a recognized gap in clinical data on frailty 
among older PWH in the region, particularly among people on long term suppressive 
ART (Siedner, 2019). 
 
Objectives 
In this study we sought to leverage data from a population-based study in rural South 
Africa to investigate whether HIV infection is associated with the frailty phenotype, 
particularly among older people on long-term ART. The primary objective was to 
compare the prevalence of frailty by HIV serostatus among older individuals in a rural 
population in South Africa with the hypothesis that PWH over the age of 50 years  
have a higher prevalence of frailty, and that the frailty phenotype manifests at 
younger ages among those with HIV. The secondary objective was to identify 
correlates of frailty in this population, including biomarkers of inflammation such as 
IL-6, D-Dimer and CRP. The hypothesis being that higher levels of these biomarkers 




The WHO multi-country Study on global AGEing and adult health (SAGE) Wellbeing 
of Older People (WOPS) cohort, at the Africa Health Research Institute (AHRI), 
gathered data on persons aged 50 years or older living with and/or affected by HIV 
over three survey waves (2010, 2013 and 2017). The WOPS cohort enrolled 
individuals selected from the AHRI (previously Africa Centre for Population Health) 
Demographic Surveillance Area (DSA) (Nyirenda et al., 2012). Data for this current 
analysis are derived from Wave 3. 
 
In Wave 1 and 2 participants were enrolled to represent 4 groups:  1) HIV positive on 
ART for ≥1 year; 2) HIV positive not on ART or on ART for ≤3 months; 3) having an 
adult child aged 18‒49 on ART for ≥1 year or for ≤3 months; 4) having an adult child 
aged 18‒49 who died of HIV related causes.  However, there has been considerable 
overlap between these groups as well as changes in availability of ART over time, so 
in our current analysis we distinguish only by HIV status. 
 
To achieve our target sample size for Wave 3 of WOPS (n=600, equivalent to the 
total sample size in both Wave 1 and Wave 2), we first recruited all previous WOPS 
participants, and sampled additional individuals as needed, to achieve full enrolment.  
All previous WOPS participants were traced and invited to participate in Wave 3.  
Stratified (by sex and HIV-status) random sampling was used to generate a list of 
new individuals to be invited. The over-sampling rate was 20%, to allow for refusals 
and/or individuals who could not be located.  Once the target enrolment had been 
met, recruitment was halted. 
 
 A total of 632 people enrolled in prior waves of the study were approached to 
participate in Wave 3. Of these 104 were deceased, 27 were not contactable, and 34 
were no longer residents of the catchment area, leaving a total of 467 individuals for 
re-engagement in WOPS 3.  An additional 366 people (n=833 total), were identified 
using stratified random sampling to ensure balance by sex and HIV serostatus, from 
the demographic health surveillance area.  
 
Out of the 833 identified a total of 726 consent visits were conducted yielding a final 
cohort of 658 participants, which met our sample size target. The remainder were 
unenrolled (n=68) due to death (n=28), out-migration from the study area (n=11), 
declined to participate (n=9) or unavailable to participate (n=20). 
 
Study Measures  
Frailty classification 
The primary outcome of interest was frailty. The Fried Frailty Index defined a clinical 
syndrome of frailty when three or more of the following were evident: weight loss in 
the past year, self-reported exhaustion, weak grip strength, slow walking speed and 
low physical activity (Fried et al., 2001).  
In our study a measure of unintentional weight loss was not included in the study 
design. The authors therefore assessed the degree of correlation between the 
measure of physical activity and of mobility to ensure that they did not measure the 
same modality.  
The assessment found that the two measures were not highly correlated: 
• Difficulty in vigorous activity vs. difficulty walking 1 km: correlation = 0.58 
• Difficulty in vigorous activity vs. time to walk 4 m: correlation = 0.34 
We therefore used a modified definition of the Fried Frailty Index consisting of the 
following measures: 1) physical activity; 2) mobility; 3) fatigue; 4) gait speed; and 5) 
grip strength. 
For the sub-measures of mobility, physical activity, and fatigue, study staff conducted 
a questionnaire from the World Health Organization’s multi-country study on global 
AGEing and adult health (SAGE) (Kowal et al., 2012). The questionnaire included 
questions about: 
• Mobility: difficulty experienced with mobility, rated from 0 (no difficulty) 
to 5 (extremely difficult or cannot complete task) 
• Physical activity: difficulty experienced in walking a long distance rated 
from 0 (no difficulty) to 5 (extremely difficult or cannot complete task) 
• Fatigue: reports of long periods of low energy and fatigue (yes/no). 
 
Gait speed 
The gait speed in metres per second (m/s) was measured using a stopwatch to time 
taken for participants to walk a distance of four meters. To note, due to missing data 
and therefore reduced power calculation, grip strength and gait speed were not 
adjusted by BMI and height in our analysis. 
 
Grip strength 
Grip strength was measured using a dynamometer (Smedley's Hand Dynamometer 
Fabrication Enterprises, New York) and results categorized according to the median 
(25th -75th percentile) by dominant hand, age, sex and region (Leong et al., 2016). 
Participants who met at least three of five criteria were classified as frail and 
participants who met one or two criteria were classified as pre-frail (Fried et al., 
2001): 
1. Self-report of severe (or greater) difficulty walking a long distance 
2. Self-report of severe (or greater) difficulty with vigorous activities 
3. Measured grip strength of the dominant hand in the lowest quintile of the 
cohort (by age, sex, and geographical region) 
4. Measured walking speed in the lowest quintile of the cohort (by sex) 
5. Self-report of an extended time of lack of energy and fatigue  
 
Height and weight (BMI) 
Height (centimetres) was measured barefoot with a stadiometer and weight 
(kilograms) on a flat surface on a calibrated Seca bathroom dial scale (Model 
SCA726). Body Mass Index was calculated and categorised according to the WHO 
guidelines of underweight (<18.5 kg/m2), normal weight/healthy (18.5–24.9 kg/m2), 
overweight (25–29.9 kg/m2), and obese (≥30 kg/m2). 
 
Blood pressure 
Systolic, diastolic blood pressure and pulse rate were measured on the left upper 
arm while the participants were seated quietly. Three measurements were taken with 
short waiting periods between measures, using a digital automatic blood pressure 
monitor. Participants were categorised as being hypertensive when their systolic BP 




Participants in Wave 3 were offered a rapid HIV test (using Abon HIV 1/2/O Triline 
HIV rapid Test (Alere Healthcare) and ONE STEP Anti HIV (1&2) test for repeat test 
(InTec Xiamen, China)), along with counselling and referral for those who tested 
positive. In addition, following consent, a Dried Blood Spot (DBS) specimen was 
collected on a filter card (Whatman 903TM, GE Healthcare, Cardiff, UK) for research 
purposes. HIV serostatus was determined by an enzyme-linked immunosorbent 
assay (ELISA) test of the DBS using the GenScreen UItra HIV Ag-Ab assay (Biorad, 
Marnes-la-Coquette, France) which has previously been adapted and validated in-
house for use on DBS. 
 
Inflammatory markers  
Interleukin 6 (IL-6), D-Dimer and C-reactive protein (CRP) biomarkers were tested 
using ELISAs designed to measure the biomarkers in serum, plasma and cell culture 
supernatant for research purposes only D-Dimer Human SimpleStep ELISA Kit; 
(Abcam, Cambridge, UK), Quantikine Human IL-6 ELISA (R&D Systems, 
Minneapolis, Minnesota, USA), and Quantikine human CRP ELISA (R&D Systems) 
were used to measure antibody responses to D-Dimer, IL-6 and CRP respectively 
from the DBS specimens collected from each of the participants.   
 
Each ELISA assay was adapted to use a 6mm punched DBS spot eluted overnight at 
4°C in the assay diluent provided in the respective kits and each protocol from this 
point onwards was followed as per the package insert. The optical densities (OD) 
were read and calculations of analyte concentrations were performed using the Gen5 
V3.03 Software package on an ELx800 Universal microplate reader (BioTek, 
Vermont, USA).  All settings and calculations were programmed as per the 
instructions in the package inserts of each kit and the results were reported in 
concentrations (ng/ml). The OD values in these cases exceed the limit of the 
instrument for determining a specific OD i.e. any sample with a concentration > 
31.500 (for D-Dimer) or >52.500 for CRP is reported as these values. Participants 
were classified as having a low, medium or high concentration of each biomarker 
based on tertiles of each biomarker within the cohort. The thresholds used for the 
classification of D-Dimer were 7.6325ng/ml and 16.21ng/ml; for IL6 the values were 
0.1ng/ml and 1.48ng/ml; and for CRP the thresholds were 13.1ng/ml and 34.8ng/ml.  
 
Statistical methods 
Participants with fewer than three frailty criterion measurements available in the 
dataset were excluded from the analysis. Values for frailty and all frailty components 
were tabulated and compared between PWH and those who were HIV negative. 
Multivariable logistic regression was performed on the primary outcome of frailty and 
on the secondary outcome of pre-frailty. As a sensitivity analysis, we performed an 
ordered logistic regression (proportional odds model) on the three level outcomes of 
non-frail (no frailty measures), pre-frail and frail. All models included HIV status, sex, 
and age group (categorized as 50-59, 60-69, 70+ years). ART status was not 
included as the vast majority (95%) of PWH were receiving treatment. To assess for 
associations between biomarkers and pre-frailty and frailty, a minimally adjusted 
logistic regression model (including age category and HIV serostatus) was conducted 
allowing a linear trend across the three tertiles of each biomarker. All point estimates 
are presented with 95% confidence intervals (CI). Analysis was performed in Stata 
version 15 (College Station, Texas, USA). 
 
Ethical review and Informed Consent 
Approval for the study was obtained from the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (BF36/09). All participants provided written informed 




A total of 614 out of 658 participants were included in this analysis (44 participants 
[6.7%] were excluded because of insufficient frailty measurements). Compared to 
those who were included in the analysis, those excluded were more likely to be male 
(51.4% vs 37.5%). The age of excluded participants was similar to those included 
(median 67.0 vs 66.3 years). Only 10, 5, and 10 of those excluded had data on D-
Dimer, IL6 and CRP levels, respectively. 
 
Of those in the analytic cohort, the majority (n=384, 62.5%) were female with an 
overall median age of 64.3 years (IQR 58.6-72.0) and approximately half were HIV 
positive (n=292, 47.6%). HIV negative respondents were slightly older (median age 
68.7 years vs 61.0, Table 1). 
 
Table 1 Cohort Profile by serostatus  
Characteristic HIV negative HIV positive Total 





Age; Median (IQR)  68.7  
(61.2 - 77.5) 
61.0  
(57.8 - 65.7) 
64.3  
(58.6 - 72.0) 
Sex=Female 182 (56.5%) 202 (69.2%) 384 (62.5%) 
Weight in kg; Median (IQR) (17 missing) 71.0  
(60.0 - 85.0) 
67.0  
(57.0 - 80.0) 
70.0  
(58.0 - 82.0) 
Systolic blood pressure; Median (IQR)  134.5  
(120.5 - 151.0) 
121.8  
(112.0 - 138.0) 
128.5  
(115.5 - 145.5) 
Diastolic blood pressure; Median (IQR)  82.0  
(74.5 - 90.5) 
78.0  
(70.8 - 86.0) 
80.5  
(73.0 - 89.0) 
Hypertensive 144 (55.3%) 78 (26.7%) 222 (36.2%) 
D-Dimer  (19 missing)       
Low 103 (32.8) 97 (34.5) 200 (33.6) 
Medium 97 (30.9%) 99 (35.2%) 196 (32.9%) 
High 114 (36.3%) 85 (30.2%) 199 (33.4%) 
IL1  (78 missing)       
High 273 (100.0%) 263 (100.0%) 536 (100.0%) 
IL6  (82 missing)       
Low 95 (34.9%) 82 (31.5%) 177 (33.3%) 
Medium 99 (36.4%) 81 (31.2%) 180 (33.8%) 
High 78 (28.7%) 97 (37.3%) 175 (32.9%) 
CRP  (16 missing)       
Low 125 (39.4%) 74 (26.3%) 199 (33.3%) 
Medium 105 (33.1%) 97 (34.5%) 202 (33.8%) 
High 87 (27.4%) 110 (39.1%) 197 (32.9%) 
  
Prevalence of Frailty  
The prevalence of pre-frailty and frailty by serostatus is given in Table 2. In total, 100 
participants (16.3%) were classified as frail having met at least three of the five 
criteria, with a similar proportion among HIV negative (17.7%) and PWH (14.7%, 
P=0.72) respondents. 
The frailty component with the highest level of observed deficit was grip strength in 
66.9% of respondents.  
The prevalence of frailty increased with age for both HIV negative and PWH (Fig.1). 
there was clear evidence that women were less likely to be pre-fail or frail than men 
in this population (OR=0.43, 95% CI 0.26-0.70 Tables 3 and 4). In secondary 
analyses, there was no evidence that the risk of being either pre-frail or frail differed 
according to HIV status (OR=0.85, 95% CI 0.541.33 and being hypertensive 
(OR=0.94,95% CI 0.61-1.47).  
 
Table 4 shows associations between a range of inflammatory biomarkers and pre-
frailty and frailty as outcomes. In the multivariable analysis, there was no evidence of 
association between any of the inflammatory biomarkers and frailty and pre-frailty 
(Table 4).  
The odds of being frail were higher in those aged 70 years and above than those 
aged between 50 and 59 years (OR=3.49, 95% CI 1.75-6.95). Females were less 
likely to be pre-frail than males (OR=0.35, 95% CI 0.20-0.60). However, there was no 
association between any of the inflammatory biomarkers and frailty and pre-frailty.. 
Table 2 Outcomes profile by serostatus  
Characteristic HIV negative HIV positive Total 
Time to walk 4 metres; Median (IQR) (57 
missing) 
8.9 (7.7 - 9.9) 8.6 (7.5 - 9.7) 8.7 (7.6 - 9.8) 
Difficulty walking 1 km  (16 missing)       
None 43 (13.9%) 38 (13.1%) 81 (13.5%) 
Mild 104 (33.7%) 115 (39.8%) 219 (36.6%) 
Moderate 73 (23.6%) 69 (23.9%) 142 (23.7%) 
Severe 42 (13.6%) 38 (13.1%) 80 (13.4%) 
Extreme 47 (15.2%) 29 (10.0%) 76 (12.7%) 
Difficulty in vigorous activity        
None 136 (42.2%) 121 (41.4%) 257 (41.9%) 
Mild 51 (15.8%) 53 (18.2%) 104 (16.9%) 
Moderate 60 (18.6%) 53 (18.2%) 113 (18.4%) 
Severe 56 (17.4%) 59 (20.2%) 115 (18.7%) 
Extreme/cannot do 19 (5.9%) 6 (2.1%) 25 (4.1%) 
Grip strength (dominant hand); Median 
(IQR)  
11.5 (8.5 - 15.0) 11.5 (8.5 - 14.8) 11.5 (8.5 - 15.0) 
Decreased energy in last 12 months  32 (9.9%) 25 (8.6%) 57 (9.3%) 
        
Frailty       
Frailty (overall) 57 (17.7%) 43 (14.7%) 100(16.3%) 
Pre-frail 214 (66.5%) 185 (63.4%) 399 (65.0%) 
Frailty indicators       
Frail: grip strength  228 (70.8%) 183 (62.7%) 411 (66.9%) 
Frail: walking speed (4m) (57 
missing) 
61 (21.6%) 47 (17.1%) 108 (19.4%) 
Frail: walking long distance (16 
missing) 
89 (28.8%) 67 (23.2%) 156 (26.1%) 
Frail: vigorous activity  75 (23.3%) 65 (22.3%) 140 (22.8%) 
Frail: energy in last 12 months  32 (9.9%) 25 (8.6%) 57 (9.3%) 
        
Frailty by age       
50-59 5 (6.8%) 15 (11.7%) 20 (10.0%) 
60-69 14 (13.6%) 19 (15.0%) 33 (14.3%) 
70-79 13 (14.6%) 9 (27.2%) 22 (18.3%) 
80+ 25 (43.8%) 0 / 4 25 (41.0%) 
        
Frailty by BMI*       
Underweight 0 / 11 6 (26.1%) 6 (17.6%) 
Healthy 18 (17.3%) 12 (10.6%) 30 (13.8%) 
Overweight 5 (6.2%) 8 (11.4%) 13 (8.7%) 
Obese 24 (21.0%) 15 (18.3%) 39 (19.9%) 
* 17 respondents missing data on BMI N=614 
 
 
Figure 1 Prevalence of frailty by age category and HIV serostatus 
 
 
Table 3 Prevalence of frailty by sex 
Frailty category Male Female Total 
Healthy 26 (11.30%)  89 (23.18%) 115 (18.73%) 
Pre-frail 174 (75.65%)   225 (58.59%) 399 (64.98%) 
Frail 30 (13.04%) 70 (18.23%)   100 (16.29%) 
Total 230 (100%)       384 (100%) 614 (100%) 
 
 
Table 4 Univariate and Multivariable logistic regression models for frailty and pre-frailty  
 
 Univariable Models Multivariable models 
Frail   
 OR* (95% CI) P-value AOR** P-value 
HIV     
     Negative Reference  Reference  
     Positive 0.80 (0.52 - 1.24) 0.319 1.06 (0.62 - 1.82) 0.828 
Age 50-59 years Reference  Reference  
60 - 69 years 1.52 (0.84 - 2.74) 0.168 1.59(0.83 - 3.05) 0.16 
70+ years 3.13 (1.77 -, 5.52) 0 3.49(1.75 - 6.95) <0.001 
Sex     
 Female Sex 1.49 (0.94 - 2.36) 0.093 1.67 (0.98 - 2.86) 0.059 
IL-6      
     Lowest Tertile 1.45 (0.84 - 2.51) 0.187 1.61 (0.91 - 2.86) 0.103 
     Middle Tertile Reference  Reference  
     Highest Tertile 0.90 (0.50 - 1.63) 0.73 0.90 (0.49 - 1.68) 0.749 
D-dimer     
     Lowest Tertile 0.94 (0.53 - 1.64)     0.822 1.09 (0.59 - 2.01) 0.793 
     Middle Tertile Reference  Reference  
     Highest Tertile 1.27 (0.75 - 2.17) 0.378 1.09 (0.61 - 1.95) 0.78 
CRP       
     Lowest Tertile 0.63 (0.36 - 1.11) 0.108 0.84 (0.46 - 1.53) 0.563 
     Middle Tertile Reference  Reference  
     Highest Tertile 1.00 (0.60 - 1.66) 0.988 1.08 (0.61- 1.91) 0.79 
 
Pre-Frail 
 Univariable Models Multivariable models 
HIV OR (95% CI) P-value AOR P-value 
     Negative Reference  Reference  
     Positive 0.67 (0.45 - 1.01) 0.055 0.72 (0.43 - 1.19) 0.196 
     
Age     
Age 50-59 years Reference  Reference  
60- 69 years 0.69 (0.43 - 1.11) 0.129 0.73 (0.43 - 1.23) 0.233 
70+ years 1.45 (0.83 - 2.53) 0.198 1.29 (0.66 - 2.52) 0.46 
Sex     
Female sex 0.42 (0.26 - 0.68) <0.001 0.35 (0.20 - 0.60) <0.001 
IL-6       
     Lowest Tertile     0.71 (0.41 - 1.24) 0.23 0.70 (0.39 - 1.25) 0.231 
     Middle Tertile Reference  Reference  
     Highest Tertile 0.57 (0.33 - 0.98) 0.043 0.58 (0.33 - 1.03) 0.063 
D-dimer     
     Lowest Tertile      0.64 (0.39 - 1.03) 0.066 0.61 (0.36 - 1.05) 0.077 
     Middle Tertile Reference  Reference  
     Highest Tertile     1.38 (0.80 - 2.39) 0.243 1.34 (0.74 - 2.44) 0.337 
CRP      
     Lowest Tertile 0.95 (0.58 - 1.56) 0.842 0.91 (0.52 - 1.59) 0.74 
     Middle Tertile Reference  Reference  
     Highest Tertile 1. 04 (0.63 - 1.72) 0.89 1.25 (0.71 - 2.19) 0.439 
*OR – odds ratio, **AOR adjusted odds ratio. 
Discussion 
In this analysis comparing the prevalence of frailty by HIV serostatus among 
community-dwelling older individuals in a rural population in South Africa, we found a 
similar prevalence of frailty between older-aged PLWH and HIV- uninfected 
comparators. Moreover, we found no differences by HIV serostatus for specific sub-
components of the frailty index measures.  Although these results are contrary to our 
primary hypothesis, the observation that PWH on ART have a similar prevalence of 
frailty as those without HIV corroborates data from elsewhere in the region. An 
analysis of data from rural South Africans over the age of 40 years found a range of 
prevalence of frailty between 5.4% and13.2%, with no difference noted by HIV 
serostatus (Payne et al., 2017). 
 
Several studies from the United States and Europe have demonstrated both higher 
rates of frailty in those with HIV and the development of the frailty phenotype at 
earlier ages than for HIV uninfected individuals (Brothers et al., 2014; Desai & 
Landay, 2010; Desquilbet et al., 2007; Levett et al., 2016). In contrast, data from sub-
Saharan Africa suggest that older people taking ART have similar or better health 
profiles than their counterparts living without HIV, including lower prevalence of 
hypertension (Kwarisiima et al., 2016; Manne-Goehler et al., 2019), obesity (Malaza, 
Mossong, Bärnighausen, & Newell, 2012; Okello et al., 2017), and carotid 
atherosclerosis (Feinstein et al., 2017; Muiru et al., 2018; Nonterah et al., 2019).  The 
reasons for the similar prevalence of frailty in those with HIV on ART and those 
without HIV infection in sub-Saharan Africa remain unclear.  It is possible that access 
to the HIV care system provides primary care in a timely fashion (because of regular 
clinic appointments), which is not always accessed by older people without HIV-
infection (Feinstein et al., 2017; Negin, Nyirenda, Seeley, & Mutevedzi, 2013). 
Alternatively, older people with HIV might represent a unique group of resilient 
survivors of the epidemic, from within the larger cohort of PWH, and such data might 
reflect a survivor effect. 
 
The overall prevalence of frailty (16.3% ) noted in this study was higher than that in 
the Agincourt study (frailty prevalence of 5.4% to 13.2% across nine frailty measure 
scores) and reported by Payne et al. (2017).  However, the prevalence was lower 
than that found in 2012 in a Cape Town population (where people with HIV were 
found to be more likely to be frail than those without (18%)) (Pathai, Lawn, et al., 
2013).  There are several possible explanations for these differences.  The Agincourt 
study (Payne et al., 2017) included 5,059 people of 40 years and older (both living 
with and without HIV), 72% of whom were aged less than 70 years. The sample in 
our study included individuals aged 50 years and older and the highest rates of frailty 
were noted among those individuals over 70 years of age.  In addition, the Agincourt 
study team measured frailty using a different set of criteria and a larger number of 
measures (nine) than in our study (five) which could account for differences in the 
results.  The age range was also different for the Cape Town study: 504 individuals 
were recruited aged 30 years and older, half of the participants were attending an 
HIV treatment centre.  Matched (by gender and age) controls were recruited from an 
HIV-prevention trial site in the same area.   Of note, the data were collected in 2011, 
before national guidelines changed to recommend provision of ART first to 
individuals with CD4 counts of ≤350 cells/µl, then ≤500 cells/µl and finally, from 2016, 
universal access to ART for all individuals living with HIV regardless of CD4 cell 
count (or WHO stage).  While older age, socio-economic status and alcohol 
consumption were associated by Pathai, Gilbert, et al. (2013, p. 47) with higher odds 
of frailty for those living with HIV; a CD4 cell count ≥500 cells /µl was also associated 
with increased rates of frailty.  Our data were collected in 2017.    
 
Finally, we found no relationship between biomarkers of inflammation or 
coagulopathy and the frailty phenotype. Future work should more exhaustively 
explore these relationships, and particularly whether there are diagnostic biomarkers 
which could help detect early stage frailty as a warning indicator. 
 
This study had a number of strengths, including a relatively large sample size of 
people 50 years and older, community-based enrolment, matching by HIV 
serostatus, and the use of biomarkers of inflammation to assess mechanisms of 
frailty. The primary limitation, however, was the use of cross-sectional sampling for 
frailty measurement, which did not support an analysis of directionality or causality of 
effects. Another limitation to be emphasized is that the Fried Frailty Index that we 
implemented was an modified version where we excluded the measure of 
unintentional weight loss because we did not have previous weight measures. The 
adapted version therefore only used 4 of the 5 measures to calculate frailty. This 
limits direct comparisons between our dataset and the data sets of similar studies in 
South Africa (Pathai, Gilbert, et al., 2013; Payne et al., 2017). The adaptation further 
decreases the strength of predictions of the presence of frailty. 
 
Conclusion 
Treated HIV infection does not appear to be associated with the frailty phenotype in 
older age, community-dwelling individuals in rural KwaZulu-Natal, South Africa. 
Future work should explore whether improved accessibility to primary care through 
HIV services might offer an avenue towards improved well-being in functioning older 
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